Gland Pharma Limited — Q4 FY25
Gland Pharma's Q4 FY25 consolidated revenue was INR 1,424.9 crore with EBITDA of INR 347.5 crore (24% margin, +100bps YoY).
neutral
medium
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q3 FY25
Cenexi revenue run rate of EUR 15M per quarter
Management targets Cenexi quarterly revenue above EUR 15 million to support EBITDA breakeven, driven by new high-speed lines.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1